Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;64(s1):S161-S189.
doi: 10.3233/JAD-179939.

Religious Orders Study and Rush Memory and Aging Project

Affiliations
Review

Religious Orders Study and Rush Memory and Aging Project

David A Bennett et al. J Alzheimers Dis. 2018.

Abstract

Background: The Religious Orders Study and Rush Memory and Aging Project are both ongoing longitudinal clinical-pathologic cohort studies of aging and Alzheimer's disease (AD).

Objectives: To summarize progress over the past five years and its implications for understanding neurodegenerative diseases.

Methods: Participants in both studies are older adults who enroll without dementia and agree to detailed longitudinal clinical evaluations and organ donation. The last review summarized findings through the end of 2011. Here we summarize progress and study findings over the past five years and discuss new directions for how these studies can inform on aging and AD in the future.

Results: We summarize 1) findings on the relation of neurobiology to clinical AD; 2) neurobiologic pathways linking risk factors to clinical AD; 3) non-cognitive AD phenotypes including motor function and decision making; 4) the development of a novel drug discovery platform.

Conclusion: Complexity at multiple levels needs to be understood and overcome to develop effective treatments and preventions for cognitive decline and AD dementia.

Keywords: Alzheimer’s disease; cognitive decline; decision making; dementia; drug discovery; epidemiology; motor function; neuropathology; omics.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Multi-layered omics, neuropathologic, and clinical data in ROSMAP.
Fig 2.
Fig 2.
Neurobiologic pathways linking risk factors to AD clinical phenotypes.
Fig. 3.
Fig. 3.
Cohort studies generating ante- and post-mortem biospecimens which are used to generate multi-layered omics data. These data feed a systems biology computation pipeline for therapeutic target nomination. There are two stages of functional validation, one with targeted proteomics using brain tissue from the same cases and the other with a variety of high throughput ex vivo models. High value targets will then move to small molecule drug screen and eventual drug selection.

Similar articles

Cited by

References

    1. Maurer K, Volk S, Gerbaldo H (1997) Auguste D and Alzheimer’s disease. Lancet 349, 1546–1549. - PubMed
    1. Amaducci LA, Rocca WA, Schoenberg BS (1986) Origin of the distinction between Alzheimer’s disease and senile dementia: how history can clarify nosology. Neurology 36, 1497–1499. - PubMed
    1. Cairns NJ, Perrin RJ, Franklin EE, Carter D, Vincent B, Xie M, Bateman RJ, Benzinger T, Friedrichsen K, Brooks WS, Halliday GM, McLean C, Ghetti B, Morris JC (2015) Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology 35, 390–400. - PMC - PubMed
    1. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain 136, 2697–2706. - PMC - PubMed
    1. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18, 691–701. - PMC - PubMed

Publication types